Guardant Health
Guardant Health Reveal Assay Gets Additional Medicare Coverage for CRC Surveillance Testing
The test was previously covered for use in colorectal cancer patients in the early postsurgical setting only.
JP Morgan Healthcare Conference, Day 1: Vertex, Bristol Myers Squibb, Gilead, Sarepta, and More
On the first day, Vertex discussed regulatory plans for a kidney disease drug, BMS and Merck talked about pipeline diversification, and Gilead offered updates on anito-cel.
Guardant Health, Cota Partner to Provide Clinicogenomic Cancer Data Resource for Biopharma
The companies believe that creating a unified set of clinical and genomic data will help biopharma clients accelerate their development of new targeted therapies.
Guardant Health, Boehringer Ingelheim Partner on Companion Diagnostic for New Lung Cancer Drug
The companies aim to establish Guardant360 CDx as a tool to identify patients with HER2 mutations eligible for treatment with the targeted drug zongertinib.
Researchers are planning a clinical trial after four metastatic FGFR2 fusion-positive pancreatic cancer patients responded to FGFR-directed therapy.